Public Health
publicado em 23/07/2012 às 10h12:00
   Dê o seu voto:

SBI supporting statement discloses the use of Truvada and HIV prevention

According to the note, three or four studies show that the use of Truvada is an auxiliary tool in reducing the infection

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



Foto: 99 Health Plus/Flickr
Drug Truvada be used for preventing the transmission of HIV
  « Previous
next »  
Drug Truvada be used for preventing the transmission of HIV

The Committee of Retrovirology of the Brazilian Society of Infectious Diseases (SBI), announced, this weekend, a statement supporting the use of the drug Truvada, approved by the FDA last week, as another form of prevention of HIV transmission.

According to the note, three or four studies show that the use of Truvada reduced the chances of infection and the medicine that combines two antriretrovirais (emtricitabine and tenofovir) is an auxiliary tool in reducing the transmission of the virus in populations at high risk of exposure.

The note closed by pointing out that, despite not having the regulated use in Brazil, the approval of Pre-Exposure Prophylaxis (PrEP) in the United States is a "great opportunity to advance discussions on preventing acquisition of HIV, especially in most vulnerable populations. "

<b> Read the full statement: </ b>

1. On July 16, 2012, the FDA (Food and Drug Administration), the regulatory agency of the Government of the United States of America, approved the use of the combined pill with two antiretroviral [tenofovir and emtricitabine (Truvada?)] For people at higher risk of acquiring Human Immunodeficiency Virus (HIV) through sexual contact. This type of prevention is called Pre-Exposure Prophylaxis (PrEP).

2. The groups cited by the FDA include the recommendation that are part of seronegative discordant couples, men who have sex with men and others at risk of acquiring HIV through sexual practice.

3. The recommendation was based on results of four studies (iPrEx, FEM-PrEP, Partners, and TDF2 PrEP), which involved men who have sex with men, transvestites, transsexuals, female and heterosexual men and women, conducted in the Americas, Africa and Thailand.

4. Three out of four studies showed that the pill Truvada? reduced the chance of participants acquiring HIV infection. Efficacy has not been demonstrated only in FEM-PrEP, which was attributed to poor adherence to pill use by participants.

5. PrEP is one more tool to assist in reducing transmission of HIV in vulnerable populations, ie, at high risk of acquiring the human immunodeficiency virus.

6. Other strategies are considered highly effective in reducing transmission: condom use barrier (condom), diagnosis and treatment of sexually transmitted diseases (STDs), adoption of safer sex practices, male circumcision, regular testing for HIV detection, counseling risk reduction and antiretroviral therapy in adequate time for people living with HIV.

PrEP does not exempt the use of these strategies, with one more element in the arsenal of measures to prevent the transmission of the virus.

7. PrEP is not yet regulated in Brazil.

The modalities for prevention using antiretroviral drugs include the prevention of vertical transmission, using sharp piercing in accidents with contaminated material after use and HIV risk sexual exposures, the latter known as Post Exposure Prophylaxis (PEP). In all these arrangements, the provision of antiretroviral drugs is done through the Unified Health System (SUS), with support from the National STD / AIDS and Viral Hepatitis, Ministry of Health of Brazil.

8. The recent approval of PrEP in the United States is a great opportunity to advance discussions on the prevention of HIV acquisition, especially the most vulnerable populations.

Source: Isaude.net
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: SBI supporting statement discloses the use of Truvada and HIV prevention
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: SBI supporting statement discloses the use of Truvada and HIV prevention


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Truvada PrEP    Fda    Brazilian Society of Infectious Diseases    the SBI notes    statement    Pre-Exposure Prophylaxis   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.